For example, meclofenamic acid, an FTO inhibitor, restores gefitinib sensitivity in non‐small cell lung cancer, and the combination of rhein (another FTO inhibitor) with tyrosine kinase inhibitors (TKIs) may benefit tyrosine kinase inhibitor‐resistant cancer patients.8 This evidence concerns the gene FTO and lung cancer.